Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGarcia Vicién, Gemma
dc.contributor.authorRuiz, Nuria
dc.contributor.authorRuffinelli, Jose Carlos
dc.contributor.authorMils, Kristel
dc.contributor.authorBañuls, María
dc.contributor.authorMicke, Patrick
dc.contributor.authorMezheyeuski, Artur
dc.date.accessioned2025-01-10T13:35:39Z
dc.date.available2025-01-10T13:35:39Z
dc.date.issued2024-12-04
dc.identifier.citationGarcia-Vicién G, Ruiz N, Micke P, Ruffinelli JC, Mils K, Bañuls M, et al. The histological growth patterns in liver metastases from colorectal cancer display differences in lymphoid, myeloid, and mesenchymal cells. MedComm. 2024 Dec;5(12):e70000.
dc.identifier.issn2688-2663
dc.identifier.urihttps://hdl.handle.net/11351/12395
dc.descriptionDesmoplasia; Hepatic metastases; Histologic growth pattern
dc.description.abstractColorectal liver metastases grow following different histologic growth patterns (HGPs), classified as desmoplastic and nondesmoplastic (dHGP, non-dHGP), being the latter associated with worst prognosis. This study aimed to investigate the tumor microenvironment (TME) between HGPs supporting different survival. Multiplexed immunohistochemical staining was performed with the Opal7 system in a 100-patients cohort to evaluate the tumor–liver interface with three different cell panels: lymphoid, myeloid, and carcinoma-associated fibroblasts. Differences between HGPs were assessed by Mann–Whitney U test with Pratt correction and Holm–Bonferroni multitest adjustment. Cytotoxic T-cells were more abundant in tumoral areas of dHGP, while non-dHGP had higher macrophages infiltration, Th2, CD163+, and Calprotectin+ cells as well as higher pSMAD2 expression. Regarding carcinoma-associated fibroblasts, several subsets expressing COL1A1 were enriched in dHGP, while αSMAlow_single cells were present at higher densities in non-dHGP. Interestingly, Calprotectin+ cells confer better prognoses in non-dHGP, identifying a subgroup of good outcome patients that unexpectedly also show an enrichment in other myeloid cells. In summary, our results illustrate different TME landscapes with respect to HGPs. dHGP presents a higher degree of immunocompetence, higher amounts of Collagen 1 as well as lesser presence of myeloid cell populations, features that might be influencing on the better prognosis of encapsulated metastases.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesMedComm;5(12)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPrognosi
dc.subjectMetàstasi
dc.subjectCòlon - Càncer
dc.subjectRecte - Càncer
dc.subjectFetge - Càncer
dc.subject.meshNeoplasm Metastasis
dc.subject.meshColorectal Neoplasms
dc.subject.meshTumor Microenvironment
dc.subject.meshLiver Neoplasms
dc.subject.meshPrognosis
dc.titleThe histological growth patterns in liver metastases from colorectal cancer display differences in lymphoid, myeloid, and mesenchymal cells
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/mco2.70000
dc.subject.decsmetástasis neoplásica
dc.subject.decsneoplasias colorrectales
dc.subject.decsmicroambiente tumoral
dc.subject.decsneoplasias hepáticas
dc.subject.decspronóstico
dc.relation.publishversionhttps://doi.org/10.1002/mco2.70000
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Garcia-Vicién G] Tumoural and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Ruiz N] Tumoural and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. Department of Pathology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain. [Micke P] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. [Ruffinelli JC] Tumoural and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. Department of Medical Oncology, Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain. [Mils K] Tumoural and Stromal Chemoresistance Group, Oncobell Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. Department of Surgery, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain. [Bañuls M] Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain. [Mezheyeuski A] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid39563958
dc.identifier.wos001369933000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record